Cystic Fibrosis: Long-Term Study of BI 3720931 Gene Therapy

We are monitoring the health of individuals with cystic fibrosis who previously received the BI 3720931 gene therapy. This study aims to assess the long-term safety and effectiveness of the treatment.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Bi 3720931

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Montpellier
Centre d'Investigation Clinique
Montpellier, France
Hopital Necker Enfants Malades
Centre d'Investigation Clinique
Montrouge, France
Giannina Gaslini Institute For Scientific Hospitalization And Care
Centro Fibrosi Cistica
Genoa, Italy

Sponsor: Boehringer Ingelheim International GmbH
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.